A study in the Journal of the American Medical Association says that SSRI’s like Paxil and Prozac are no more effective in treating depression than a placebo pill. That means they are 33 per cent effective, which is the percent of patients who will respond well to a sugar pill.
“No matter how DSM V will be written, it will be flawed. There is no psychiatric diagnosis which has an objective measure. At the moment, all diagnoses are clinical diagnoses, meaning they are subjective. This is a field of humility. There is a lot that we do not know. I think there should be an introduction to DSM V which clearly states that this book is a product of work groups…” – Shirah Vollmer, MD
Genita Petralli, president of nonprofit Green Body and Mind, director of Patient Services at Alternative to Meds Clinic, and an author of several books, says it’s her mission to “educate all those interested in what is causing the epidemic mental health crisis of today, how to avoid it, how to get off psychiatric drugs if you are on them now, and why toxic drugs should not ever be called medicine.” To that end, Petralli launched the area’s first Green Mental Health Care Day, a day where speakers and healers came together to address the problems of psychiatric drugs and offer several alternative solutions.
Some of the most acrimonious arguments stem from worries about the pharmaceutical industry’s influence over psychiatry. This has led to the spotlight being turned on the financial ties of those in charge of revising the manual, and has made any diagnostic changes that could expand the use of drugs especially controversial.
The disorder is a branch of “female sexual dysfunction,” a widely debated term that involves everything from an inability to reach orgasm to a lack of desire. Described as a “Viagra-like drug for women” by one of the drug trials’ principal investigators, the former antidepressant flibanserin is prompting an outcry from critics who say female sexual dysfunction is a disorder the pharmaceutical industry has conjured as an attempt to capitalize on women’s complex sexuality.